231 related articles for article (PubMed ID: 38263212)
1. Transcriptomic and proteomic analysis of tumor suppressive effects of GZ17-6.02 against mycosis fungoides.
Bordeaux ZA; Reddy SV; Choi J; Braun G; McKeel J; Lu W; Yossef SM; Ma EZ; West CE; Kwatra SG; Kwatra MM
Sci Rep; 2024 Jan; 14(1):1955. PubMed ID: 38263212
[TBL] [Abstract][Full Text] [Related]
2. GZ17-6.02 interacts with bexarotene to kill mycosis fungoides cells.
Booth MR; Booth L; Roberts JL; West C; Dent P
Oncotarget; 2024 Feb; 15():124-133. PubMed ID: 38329728
[TBL] [Abstract][Full Text] [Related]
3. Differential Response of Mycosis Fungoides Cells to Vorinostat.
Bordeaux ZA; Reddy SV; Lee K; Lu W; Choi J; Miller M; Roberts C; Pollizzi A; Kwatra SG; Kwatra MM
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175780
[TBL] [Abstract][Full Text] [Related]
4. CCR7 expression correlates with subcutaneous involvement in mycosis fungoides skin lesions and promotes migration of mycosis fungoides cells (MyLa) through mTOR activation.
Hu SC; Lin CL; Hong CH; Yu HS; Chen GS; Lee CH
J Dermatol Sci; 2014 Apr; 74(1):31-8. PubMed ID: 24411580
[TBL] [Abstract][Full Text] [Related]
5. Understanding Cell Lines, Patient-Derived Xenograft and Genetically Engineered Mouse Models Used to Study Cutaneous T-Cell Lymphoma.
Gill RPK; Gantchev J; Martínez Villarreal A; Ramchatesingh B; Netchiporouk E; Akilov OE; Ødum N; Gniadecki R; Koralov SB; Litvinov IV
Cells; 2022 Feb; 11(4):. PubMed ID: 35203244
[TBL] [Abstract][Full Text] [Related]
6. Advanced-stage mycosis fungoides: role of the signal transducer and activator of transcription 3, nuclear factor-κB and nuclear factor of activated T cells pathways.
Pérez C; Mondéjar R; García-Díaz N; Cereceda L; León A; Montes S; Durán Vian C; Pérez Paredes MG; González-Morán A; Alegre de Miguel V; Sanz Anquela JM; Frias J; Limeres MA; González LM; Martín Dávila F; Beltrán M; Mollejo M; Méndez JR; González MA; González García J; López R; Gómez A; Izquierdo F; Ramos R; Camacho C; Rodriguez-Pinilla SM; Martínez N; Vaqué JP; Ortiz-Romero PL; Piris MA
Br J Dermatol; 2020 Jan; 182(1):147-155. PubMed ID: 31049933
[TBL] [Abstract][Full Text] [Related]
7. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
8. Constitutive expression of NF-kappa B is a characteristic feature of mycosis fungoides: implications for apoptosis resistance and pathogenesis.
Izban KF; Ergin M; Qin JZ; Martinez RL; Pooley RJ JR; Saeed S; Alkan S
Hum Pathol; 2000 Dec; 31(12):1482-90. PubMed ID: 11150373
[TBL] [Abstract][Full Text] [Related]
9. A novel combination of isovanillin, curcumin, and harmine (GZ17-6.02) enhances cell death and alters signaling in actinic keratoses cells when compared to individual components and two-component combinations.
Bordeaux ZA; Kwatra SG; Booth L; Dent P
Anticancer Drugs; 2023 Apr; 34(4):544-550. PubMed ID: 36847046
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA expression in early mycosis fungoides is distinctly different from atopic dermatitis and advanced cutaneous T-cell lymphoma.
Ralfkiaer U; Lindahl LM; Litman T; Gjerdrum LM; Ahler CB; Gniadecki R; Marstrand T; Fredholm S; Iversen L; Wasik MA; Bonefeld CM; Geisler C; Krejsgaard T; Glue C; Røpke MA; Woetmann A; Skov L; Grønbæk K; Odum N
Anticancer Res; 2014 Dec; 34(12):7207-17. PubMed ID: 25503151
[TBL] [Abstract][Full Text] [Related]
11. Cell signaling in cutaneous T-cell lymphoma microenvironment: promising targets for molecular-specific treatment.
Rendón-Serna N; Correa-Londoño LA; Velásquez-Lopera MM; Bermudez-Muñoz M
Int J Dermatol; 2021 Dec; 60(12):1462-1480. PubMed ID: 33835479
[TBL] [Abstract][Full Text] [Related]
12. Chlormethine Gel for the Treatment of Mycosis Fungoides (Cutaneous T-cell Lymphoma) in Canada.
Gniadecki R; Paron E
Skin Therapy Lett; 2023 Mar; 28(2):1-5. PubMed ID: 37054720
[TBL] [Abstract][Full Text] [Related]
13. Potent Antitumor Effects of a Combination of Three Nutraceutical Compounds.
Vishwakarma V; New J; Kumar D; Snyder V; Arnold L; Nissen E; Hu Q; Cheng N; Miller D; Thomas AR; Shnayder Y; Kakarala K; Tsue TT; Girod DA; Thomas SM
Sci Rep; 2018 Aug; 8(1):12163. PubMed ID: 30111862
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Evidence for Targeting PI3K/mTOR Signaling with Dual-Inhibitors as a Therapeutic Strategy against Cutaneous T-Cell Lymphoma.
Bresin A; Cristofoletti C; Caprini E; Cantonetti M; Monopoli A; Russo G; Narducci MG
J Invest Dermatol; 2020 May; 140(5):1045-1053.e6. PubMed ID: 31682844
[TBL] [Abstract][Full Text] [Related]
15. T-cell receptor gene rearrangement in canine mycosis fungoides: further support for a canine model of cutaneous T-cell lymphoma.
Fivenson DP; Saed GM; Beck ER; Dunstan RW; Moore PF
J Invest Dermatol; 1994 Feb; 102(2):227-30. PubMed ID: 7906287
[TBL] [Abstract][Full Text] [Related]
16. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
17. miR-223 regulates cell growth and targets proto-oncogenes in mycosis fungoides/cutaneous T-cell lymphoma.
McGirt LY; Adams CM; Baerenwald DA; Zwerner JP; Zic JA; Eischen CM
J Invest Dermatol; 2014 Apr; 134(4):1101-1107. PubMed ID: 24304814
[TBL] [Abstract][Full Text] [Related]
18. Roles of OX40 and OX40 Ligand in Mycosis Fungoides and Sézary Syndrome.
Kawana Y; Suga H; Kamijo H; Miyagaki T; Sugaya M; Sato S
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830466
[TBL] [Abstract][Full Text] [Related]
19. CD147-Cyclophilin a Interactions Promote Proliferation and Survival of Cutaneous T-Cell Lymphoma.
Sakamoto M; Miyagaki T; Kamijo H; Oka T; Boki H; Takahashi-Shishido N; Suga H; Sugaya M; Sato S
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360654
[TBL] [Abstract][Full Text] [Related]
20. Aberrant CD137 ligand expression induced by GATA6 overexpression promotes tumor progression in cutaneous T-cell lymphoma.
Kamijo H; Miyagaki T; Shishido-Takahashi N; Nakajima R; Oka T; Suga H; Sugaya M; Sato S
Blood; 2018 Nov; 132(18):1922-1935. PubMed ID: 30194255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
